Mustang Bio, Inc.
$0.74
▲
0.65%
2026-04-21 08:03:01
www.mustangbio.com
NCM: MBIO
Explore Mustang Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.61 M
Current Price
$0.74
52W High / Low
$7 / $0.53
Stock P/E
—
Book Value
$1.31
Dividend Yield
—
ROCE
-25.13%
ROE
-67.93%
Face Value
—
EPS
$-0.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
2.18
Debt / Equity
0
Current Ratio
2.22
Quick Ratio
2.22
Forward P/E
-2
Price / Sales
—
Enterprise Value
$-11.96 M
EV / EBITDA
4.99
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | aTyr Pharma, Inc. | $0.85 | — | $83.68 M | — | -99.71% | -1.08% | $7.29 / $0.64 | $0.69 |
| 2. | Grace Therapeutics, Inc. | $4.59 | — | $71.03 M | — | -23.81% | -10.22% | $5.18 / $2 | $4.19 |
| 3. | ORIC Pharmaceuticals, Inc. | $10.89 | — | $1.09 B | — | -36.81% | -41.27% | $14.93 / $4.52 | $3.9 |
| 4. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
| 5. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 6. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
| 7. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.67 M | -0.62 M | -0.89 M | -0.25 M | 0.03 M | — |
| Net Profit | -0.54 M | -0.47 M | -0.76 M | -0.15 M | -0.95 M | — |
| EPS in Rs | -0.08 | -0.07 | -0.11 | -0.02 | -0.14 | -1.96 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -2.43 M | -12.55 M | -50.73 M | -76.16 M |
| Net Profit | -1.92 M | -15.75 M | -51.6 M | -77.53 M |
| EPS in Rs | -0.29 | -2.34 | -7.67 | -11.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 17.59 M | 9.31 M | 17.74 M | 92.42 M |
| Total Liabilities | 8.06 M | 13.18 M | 17.62 M | 46.15 M |
| Equity | 9.53 M | -3.87 M | 0.12 M | 46.27 M |
| Current Assets | 17.59 M | 8.61 M | 11.35 M | 78.85 M |
| Current Liabilities | 7.91 M | 12.61 M | 15.37 M | 15.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.26 M | -11.41 M | -49.48 M | -65.07 M |
| Investing CF | 1.17 M | 0 M | 5.89 M | -2.95 M |
| Financing CF | 14.53 M | 11.27 M | -26.08 M | 34.06 M |
| Free CF | -5.26 M | -11.41 M | -49.59 M | -68.14 M |
| Capex | — | — | -0.11 M | -3.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 69.47% | 33.44% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-01-16 | 1:0.02 |
| 2023-04-04 | 1:0.0666667 |